Skip to main content
. 2013 Apr 30;45(12):449–461. doi: 10.1152/physiolgenomics.00166.2012

Fig. 5.

Fig. 5.

A: quantitative real-time PCR analysis of PPAR coactivator (PGC)-1α, estrogen-related receptor (ERR)-α, and peroxisome proliferator-activator receptor (PPAR)-α in control, failing (SuHx), carvedilol-treated (carvedilol), and metoprolol-treated (metoprolol) RVs (*P < 0.01, #P < 0.001). B: Top: quantitative real-time PCR analysis of PGC-1α in control, failing (SuHx), and carvedilol-treated (carvedilol) RVs (*P < 0.01) Bottom: Western blot analysis of PGC-1α in failing (SuHx) and carvedilol-treated (carvedilol) RVs. C: quantitative real-time PCR analysis of the PGC-1α downstream genes CD36, ACSL1, CPT1α, CPT1β, CPT2, and ACADM in control, failing (SuHx), and carvedilol-treated (carvedilol) RVs (*P < 0.01, #P < 0.001). D: mitochondrial efficiency measured as ADP/O ratio in control, failing (SuHx), and carvedilol-treated (carvedilol) RVs (*P < 0.01).